Cell-Free DNA: An Upcoming Biomarker in Transplantation

American Journal of Transplantation

Volumn 15, Issue 10, 2015, Pages 2541-2551

  Gielis, E M ^a,b   Ledeganck, K J ^a   De Winter, B Y ^a   Del Favero, J ^c   Bosmans, J L ^a,d   Claas, F H J ^b   Abramowicz, D ^a,d   Eikmans, M ^b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Multiplicom N V ^*  (Belgium)

^d ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

biomarker; clinical research practice; kidney transplantation nephrology; molecular biology; molecular biology: DNA; organ transplantation in general; rejection: acute; translational research science

Indexed keywords

BIOLOGICAL MARKER; DNA; DONOR DERIVED CELL FREE DEOXYRIBONUCLEIC ACID; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ARTICLE; DIGITAL DROPLET POLYMERASE CHAIN REACTION; DNA ISOLATION; DNA SEQUENCE; HUMAN; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; LIVER; LIVER TRANSPLANTATION; MASSIVE PARALLEL SEQUENCING; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; BLOOD; CELL FREE SYSTEM; DONOR; GENETICS; GRAFT REJECTION; HIGH THROUGHPUT SEQUENCING; ISOLATION AND PURIFICATION;

BIOMARKERS; CELL-FREE SYSTEM; DNA; GRAFT REJECTION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; ORGAN TRANSPLANTATION; TISSUE DONORS;

EID: 84941933577     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13387     Document Type: Article

References (61)

1. Lucey MR, Terrault N, Ojo L, et al., Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl 2013; 19: 3-26.
2. Flechner SM, Kobashigawa J, Klintmalm G,. Calcineurin inhibitor-sparing regimens in solid organ transplantation: Focus on improving renal function and nephrotoxicity. Clin Transplant 2008; 22: 1-15.
3. Smith JM, Skeans MA, Horslen SP, et al., OPTN/SRTR 2013 Annual Data Report: Intestine. Am J Transplant 2015; 15 Supp 1: 1-16.
4. Colvin-Adams M, Smith JM, Heubner BM, et al., OPTN/SRTR 2013 Annual Data Report: Heart. Am J Transplant 2015; 15 Supp 1: 1-28.
5. Valapour M, Skeans MA, Heubner BM, et al., OPTN/SRTR 2013 Annual Data Report: Lung. Am J Transplant 2015; 15 Supp 1: 1-28.
6. Kim WR, Lake JR, Smith JM, et al., OPTN/SRTR 2013 Annual Data Report: Liver. Am J Transplant 2015; 15 Supp 1: 1-28.
7. Kandaswamy R, Skeans MA, Gustafson SK, et al., OPTN/SRTR 2013 Annual Data Report: Pancreas. Am J Transplant 2015; 15 Supp 1: 1-20.
8. Matas AJ, Smith JM, Skeans MA, et al., OPTN/SRTR 2013 Annual Data Report: Kidney. Am J Transplant 2015; 15 Supp 1: 1-34.
9. Voskuil MD, Mittal S, Sharples EJ, et al., Improving monitoring after pancreas transplantation alone: Fine-tuning of an old technique. Clin Transplant 2014; 28: 1047-1053.
10. Kidney disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9: S1-S157.
11. Colvin RB, Smith RN,. Antibody-mediated organ-allograft rejection. Nat Rev Immunol 2005; 5: 807-817.
12. Costanzo MR, Dipchand A, Starling R, et al., The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010; 29: 914-956.
13. Hopkins PM, Aboyoun CL, Chhajed PN, et al., Prospective analysis of 1,235 transbronchial lung biopsies in lung transplant recipients. J Heart Lung Transplant 2002; 21: 1062-1067.
14. McWilliams TJ, Williams TJ, Whitford HM, Snell GI,. Surveillance bronchoscopy in lung transplant recipients: Risk versus benefit. J Heart Lung Transplant 2008; 27: 1203-1209.
15. Kfoury AG, Snow GL, Budge D, et al., A longitudinal study of the course of asymptomatic antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2012; 31: 46-51.
16. Orandi BJ, Chow EH, Hsu A, et al., Quantifying renal allograft loss following early antibody-mediated rejection. Am J Transplant 2015; 15: 489-498.
17. Nankivell BJ, Chapman JR,. The significance of subclinical rejection and the value of protocol biopsies. Am J Transplant 2006; 6: 2006-2012.
18. Deng MC, Eisen HJ, Mehra MR, et al., Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 2006; 6: 150-160.
19. Roedder S, Sigdel T, Salomonis N, et al., The kSORT assay to detect renal transplant patients at high risk for acute rejection: Results of the multicenter AART study. PLoS Med 2014; 11: e1001759.
20. Abecassis M, Kaplan B,. Transplantation: Biomarkers in transplantation-the devil is in the detail. Nat Rev Nephrol 2015; 11: 204-205.
21. Lo YM, Tein MS, Pang CC, Yeung CK, Tong KL, Hjelm NM,. Presence of donor-specific DNA in plasma of kidney and liver-transplant recipients. Lancet 1998; 351: 1329-1330.
22. Zhang J, Tong KL, Li PK, et al., Presence of donor- and recipient-derived DNA in cell-free urine samples of renal transplantation recipients: Urinary DNA chimerism. Clin Chem 1999; 45: 1741-1746.
23. Suzuki N, Kamataki A, Yamaki J, Homma Y,. Characterization of circulating DNA in healthy human plasma. Clin Chim Acta 2008; 387: 55-58.
24. Zheng YW, Chan KC, Sun H, et al., Nonhematopoietically derived DNA is shorter than hematopoietically derived DNA in plasma: A transplantation model. Clin Chem 2012; 58: 549-558.
25. Beck J, Urnovitz HB, Riggert J, Clerici M, Schutz E,. Profile of the circulating DNA in apparently healthy individuals. Clin Chem 2009; 55: 730-738.
26. Jahr S, Hentze H, Englisch S, et al., DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001; 61: 1659-1665.
27. Stroun M, Lyautey J, Lederrey C, Olson-Sand A, Anker P,. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta 2001; 313: 139-142.
28. Gahan PB, Anker P, Stroun M,. Metabolic DNA as the origin of spontaneously released DNA? Ann N Y Acad Sci 2008; 1137: 7-17.
29. Rogers JC, Boldt D, Kornfeld S, Skinner A, Valeri CR,. Excretion of deoxyribonucleic acid by lymphocytes stimulated with phytohemagglutinin or antigen. Proc Natl Acad Sci USA 1972; 69: 1685-1689.
30. Lui YY, Chik KW, Chiu RW, Ho CY, Lam CW, Lo YM,. Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin Chem 2002; 48: 421-427.
31. Lui YY, Woo KS, Wang AY, et al., Origin of plasma cell-free DNA after solid organ transplantation. Clin Chem 2003; 49: 495-496.
32. Botezatu I, Serdyuk O, Potapova G, et al., Genetic analysis of DNA excreted in urine: A new approach for detecting specific genomic DNA sequences from cells dying in an organism. Clin Chem 2000; 46: 1078-1084.
33. Su YH, Wang M, Brenner DE, et al., Human urine contains small, 150 to 250 nucleotide-sized, soluble DNA derived from the circulation and may be useful in the detection of colorectal cancer. J Mol Diagn 2004; 6: 101-107.
34. Snyder TM, Khush KK, Valantine HA, Quake SR,. Universal noninvasive detection of solid organ transplant rejection. Proc Natl Acad Sci USA 2011; 108: 6229-6234.
35. Zhong XY, Hahn D, Troeger C, et al., Cell-free DNA in urine: A marker for kidney graft rejection, but not for prenatal diagnosis? Ann N Y Acad Sci 2001; 945: 250-257.
36. Zhang Z, Ohkohchi N, Sakurada M, et al., Analysis of urinary donor-derived DNA in renal transplant recipients with acute rejection. Clin Transplant 2002; 16: 45-50.
37. Garcia Moreira V, Prieto Garcia B, Baltar Martin JM, Ortega Suarez F, Alvarez FV,. Cell-free DNA as a noninvasive acute rejection marker in renal transplantation. Clin Chem 2009; 55: 1958-1966.
38. Sigdel TK, Vitalone MJ, Tran TQ, et al., A rapid noninvasive assay for the detection of renal transplant injury. Transplantation 2013; 96: 97-101.
39. Macher HC, Suarez-Artacho G, Guerrero JM, et al., Monitoring of transplanted liver health by quantification of organ-specific genomic marker in circulating DNA from receptor. PLoS ONE 2014; 9: e113987.
40. Gadi VK, Nelson JL, Boespflug ND, Guthrie KA, Kuhr CS,. Soluble donor DNA concentrations in recipient serum correlate with pancreas-kidney rejection. Clin Chem 2006; 52: 379-382.
41. Bruno DL, Ganesamoorthy D, Thorne NP, et al., Use of copy number deletion polymorphisms to assess DNA chimerism. Clin Chem 2014; 60: 1105-1114.
42. Beck J, Bierau S, Balzer S, et al., Digital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury. Clin Chem 2013; 59: 1732-1741.
43. Kanzow P, Kollmar O, Schutz E, et al., Graft-derived cell-free DNA as an early organ integrity biomarker after transplantation of a marginal HELLP syndrome donor liver. Transplantation 2014; 98: e43-e45.
44. Oellerich M, Schutz E, Kanzow P, et al., Use of graft-derived cell-free DNA as an organ integrity biomarker to reexamine effective tacrolimus trough concentrations after liver transplantation. Ther Drug Monit 2014; 36: 136-140.
45. De Vlaminck I, Valantine HA, Snyder TM, et al., Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. Sci Transl Med 2014; 6: 241ra277.
46. Barrett AN, Zimmermann BG, Wang D, Holloway A, Chitty LS,. Implementing prenatal diagnosis based on cell-free fetal DNA: Accurate identification of factors affecting fetal DNA yield. PLoS ONE 2011; 6: e25202.
47. Angert RM, LeShane ES, Lo YM, Chan LY, Delli-Bovi LC, Bianchi DW,. Fetal cell-free plasma DNA concentrations in maternal blood are stable 24 hours after collection: analysis of first-and third-trimester samples. Clin Chem 2003; 49: 195-198.
48. Wong D, Moturi S, Angkachatchai V, et al., Optimizing blood collection, transport and storage conditions for cell free DNA increases access to prenatal testing. Clin Biochem 2013; 46: 1099-1104.
49. Norton SE, Lechner JM, Williams T, Fernando MR,. A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR. Clin Biochem 2013; 46: 1561-1565.
50. Holdenrieder S, Von Pawel J, Nagel D, Stieber P,. Long-term stability of circulating nucleosomes in serum. Anticancer Res 2010; 30: 1613-1615.
51. Sozzi G, Roz L, Conte D, et al., Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantification assays. J Natl Cancer Inst 2005; 97: 1848-1850.
52. van der Vaart M, Pretorius PJ,. Is the role of circulating DNA as a biomarker of cancer being prematurely overrated? Clin Biochem 2010; 43: 26-36.
53. Lee TH, Montalvo L, Chrebtow V, Busch MP,. Quantitation of genomic DNA in plasma and serum samples: Higher concentrations of genomic DNA found in serum than in plasma. Transfusion 2001; 41: 276-282.
54. Ito K, Minamiura N, Yamamoto T,. Human urine DNase I: Immunological identity with human pancreatic DNase I, and enzymic and proteochemical properties of the enzyme. J Biochem 1984; 95: 1399-1406.
55. Murai K, Yamanaka M, Akagi K, Anai M,. Purification and properties of deoxyribonuclease II from human urine. J Biochem 1980; 87: 1097-1103.
56. Milde A, Haas-Rochholz H, Kaatsch HJ,. Improved DNA typing of human urine by adding EDTA. Int J Legal Med 1999; 112: 209-210.
57. Wang M, Block TM, Steel L, Brenner DE, Su YH,. Preferential isolation of fragmented DNA enhances the detection of circulating mutated k-ras DNA. Clin Chem 2004; 50: 211-213.
58. Shekhtman EM, Anne K, Melkonyan HS, Robbins DJ, Warsof SL, Umansky SR,. Optimization of transrenal DNA analysis: Detection of fetal DNA in maternal urine. Clin Chem 2009; 55: 723-729.
59. Li Y, Hahn D, Zhong XY, Thomson PD, Holzgreve W, Hahn S,. Detection of donor-specific DNA polymorphisms in the urine of renal transplant recipients. Clin Chem 2003; 49: 655-658.
60. Costa C, Cavallo R,. Polyomavirus-associated nephropathy. World J Transplant 2012; 2: 84-94.
61. Garcia Moreira V, Prieto Garcia B, de la Cera Martinez T, Alvarez Menendez FV,. Elevated transrenal DNA (cell-free urine DNA) in patients with urinary tract infection compared to healthy controls. Clin Biochem 2009; 42: 729-731.